X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA FRESENIUS KABI ONCO. SHASUN PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 123.9 22.1 559.9% View Chart
P/BV x 8.5 3.1 274.1% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
FRESENIUS KABI ONCO.
Mar-13
SHASUN PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs94176 53.5%   
Low Rs4679 58.1%   
Sales per share (Unadj.) Rs214.237.7 568.3%  
Earnings per share (Unadj.) Rs5.35.1 104.8%  
Cash flow per share (Unadj.) Rs15.86.7 235.3%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.342.5 125.4%  
Shares outstanding (eoy) m56.62158.23 35.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.4 9.7%   
Avg P/E ratio x13.125.0 52.4%  
P/CF ratio (eoy) x4.418.9 23.3%  
Price / Book Value ratio x1.33.0 43.8%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,95820,135 19.7%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m2,164703 307.7%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m12,1275,963 203.4%  
Other income Rs m22918 1,274.2%   
Total revenues Rs m12,3565,981 206.6%   
Gross profit Rs m1,0091,430 70.6%  
Depreciation Rs m594258 230.2%   
Interest Rs m415-26 -1,596.5%   
Profit before tax Rs m2301,216 18.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m-73342 -21.3%   
Profit after tax Rs m302806 37.5%  
Gross profit margin %8.324.0 34.7%  
Effective tax rate %-31.728.1 -112.5%   
Net profit margin %2.513.5 18.4%  
BALANCE SHEET DATA
Current assets Rs m6,8845,102 134.9%   
Current liabilities Rs m8,4562,385 354.5%   
Net working cap to sales %-13.045.6 -28.5%  
Current ratio x0.82.1 38.1%  
Inventory Days Days62150 41.1%  
Debtors Days Days108113 94.9%  
Net fixed assets Rs m4,9705,148 96.5%   
Share capital Rs m113158 71.6%   
"Free" reserves Rs m2,8756,556 43.9%   
Net worth Rs m3,0206,732 44.9%   
Long term debt Rs m1,817952 190.9%   
Total assets Rs m13,34710,388 128.5%  
Interest coverage x1.6-45.8 -3.4%   
Debt to equity ratio x0.60.1 425.4%  
Sales to assets ratio x0.90.6 158.3%   
Return on assets %5.47.5 71.6%  
Return on equity %10.012.0 83.6%  
Return on capital %13.314.6 91.2%  
Exports to sales %46.474.5 62.2%   
Imports to sales %14.224.8 57.5%   
Exports (fob) Rs m5,6224,441 126.6%   
Imports (cif) Rs m1,7281,477 116.9%   
Fx inflow Rs m5,8435,298 110.3%   
Fx outflow Rs m2,1731,772 122.6%   
Net fx Rs m3,6693,525 104.1%   
CASH FLOW
From Operations Rs m3981,274 31.2%  
From Investments Rs m-1,635-1,204 135.8%  
From Financial Activity Rs m1,309-196 -667.3%  
Net Cashflow Rs m71-126 -56.4%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 3.6 0.3 1,200.0%  
FIIs % 17.6 9.6 183.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 9.1 435.2%  
Shareholders   20,750 42,599 48.7%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS